- Home
- ABUS vs CPAC Comparison
ABUS vs CPAC Comparison
Compare ABUS & CPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- CPAC
- Stock Information
- Founded
- ABUS 2005
- CPAC 1949
- Country
- ABUS United States
- CPAC Peru
- Employees
- ABUS N/A
- CPAC N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- CPAC Building Materials
- Sector
- ABUS Health Care
- CPAC Industrials
- Exchange
- ABUS Nasdaq
- CPAC Nasdaq
- Market Cap
- ABUS 711.2M
- CPAC 580.5M
- IPO Year
- ABUS N/A
- CPAC 2012
- Fundamental
- Price
- ABUS $4.20
- CPAC $6.78
- Analyst Decision
- ABUS Strong Buy
- CPAC Hold
- Analyst Count
- ABUS 3
- CPAC 1
- Target Price
- ABUS $5.67
- CPAC $6.40
- AVG Volume (30 Days)
- ABUS 1.0M
- CPAC 4.8K
- Earning Date
- ABUS 11-05-2025
- CPAC 10-27-2025
- Dividend Yield
- ABUS N/A
- CPAC 7.39%
- EPS Growth
- ABUS N/A
- CPAC 26.68
- EPS
- ABUS N/A
- CPAC 0.14
- Revenue
- ABUS $15,416,000.00
- CPAC $572,828,408.00
- Revenue This Year
- ABUS $138.02
- CPAC N/A
- Revenue Next Year
- ABUS N/A
- CPAC N/A
- P/E Ratio
- ABUS N/A
- CPAC $9.57
- Revenue Growth
- ABUS 53.23
- CPAC 3.37
- 52 Week Low
- ABUS $2.71
- CPAC $5.10
- 52 Week High
- ABUS $4.73
- CPAC $6.90
- Technical
- Relative Strength Index (RSI)
- ABUS 84.85
- CPAC 66.58
- Support Level
- ABUS $3.60
- CPAC $6.67
- Resistance Level
- ABUS $4.10
- CPAC $6.82
- Average True Range (ATR)
- ABUS 0.17
- CPAC 0.17
- MACD
- ABUS 0.06
- CPAC 0.04
- Stochastic Oscillator
- ABUS 83.33
- CPAC 85.54
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About CPAC Cementos Pacasmayo S.A.A. (Each representing five)
Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.